In 2024, we achieved 33 percent growth, bringing our total growth to 70 percent over the past three years. This reflects our long-term focus on delivering high-quality bioanalytical services and innovative solutions that support clinical research in cardiometabolic diseases.
As part of our global strategy, we are expanding our presence in the U.S., strengthening our ability to support life science organizations with local expertise and flexible service.
CEO Jörgen Dahlström comments:
“We are incredibly proud of the growth we have achieved over the past few years and view our expansion into the U.S. as a natural step forward. This move enables us to provide a more flexible, business-driven service with a local presence. It also positions us to better address the growing global demand for reliable solutions in the cardiometabolic field. Our success reflects the expertise of our team, our strong customer focus, and our ability to deliver results.”
With a strong track record of collaboration and deep industry knowledge, we aim to be more than a supplier. Our goal is to be a strategic partner in the efficient, safe and high-quality execution of clinical studies.
